SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Patrick J. Finn, Ph.D., to the newly-created position of chief commercial officer. Dr. Finn previously served as senior vice president of commercial operations.
“Paddy built our global sales, marketing and support organizations from the ground up, led the launch of both our commercial synthetic biology and genomics offerings, and continues to drive top line growth and market penetration for all business segments,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We look forward to Paddy’s leadership in his new role overseeing the commercial development for our synbio and genomics product lines, but also in our medium- and longer-term market opportunities in biopharma and DNA data storage.”
“It is an honor to work with the incredibly talented and motivated individuals at Twist, and as a team we have already achieved a tremendous amount in driving disruptive products and technology into the markets we serve,” commented Dr. Finn. “I look forward to building on the strong foundation we have created in our sales, marketing and support organizations to accelerate our growth and amplify the important work we are doing to supply synthetic DNA-based products that enable our customers to improve health and sustainability.”
In his new role, Dr. Finn will be responsible for global commercialization of all products in addition to commercial development activities. Dr. Finn joined Twist Bioscience in 2015, building the company’s sales force in advance of the launch of its commercial synthetic DNA products. He subsequently led the commercialization of the company’s second product line focused on target enrichment for next generation sequencing applications. He joined Twist from Enzymatics (now QIAGEN), where he was vice president of sales, leading commercial activities for North America and Europe. Prior to Enzymatics, he held positions with increasing commercial focus, including director of business development at Agilent Technologies, director of product development for Beckman Coulter, and multiple technical roles in product development within Invitrogen and GE Healthcare/Amersham International. Dr. Finn also served on the scientific advisory boards of Lasergen and Enzymatics. He holds a Ph.D. in nucleic acid chemistry from Southampton University and a B.Sc. Hons in Chemistry from Heriot-Watt University.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2019. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
All Twist Bioscience products are Research Use Only.